acetaminophen and Bruise
acetaminophen has been researched along with Bruise in 10 studies
Acetaminophen: Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as a common analgesic, but may cause liver, blood cell, and kidney damage.
paracetamol : A member of the class of phenols that is 4-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare acetaminophen extended release 1,300 mg 3 times daily and ibuprofen 400 mg 3 times daily for treatment of signs and symptoms of grade I or II lateral ankle sprains." | 9.12 | Randomized controlled noninferiority trial to compare extended release acetaminophen and ibuprofen for the treatment of ankle sprains. ( Dalton, JD; Schweinle, JE, 2006) |
| "To compare acetaminophen extended release 1,300 mg 3 times daily and ibuprofen 400 mg 3 times daily for treatment of signs and symptoms of grade I or II lateral ankle sprains." | 5.12 | Randomized controlled noninferiority trial to compare extended release acetaminophen and ibuprofen for the treatment of ankle sprains. ( Dalton, JD; Schweinle, JE, 2006) |
| "Optimizing postoperative pain control is an important aspect in perioperative patient care." | 2.71 | Pre-incision infiltration of local anesthetic reduces postoperative pain with no effects on bruising and wound cosmesis after thyroid surgery. ( Bagul, A; Brook, NR; Metcalfe, MS; Nicholson, ML; Taha, R, 2005) |
| "Acute soft tissue injuries are common and costly." | 2.66 | Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury. ( Dalziel, SR; Jones, P; Lamdin, R, 2020) |
| " The evidence was usually either low quality or very low quality, reflecting study limitations, indirectness such from as suboptimal dosing of single comparators, imprecision, or one or more of these." | 2.52 | Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury. ( Dalziel, SR; Frampton, C; Jones, P; Lamdin, R; Miles-Chan, JL, 2015) |
Research
Studies (10)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (30.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 2 (20.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Jones, P | 2 |
| Lamdin, R | 2 |
| Dalziel, SR | 2 |
| Miles-Chan, JL | 1 |
| Frampton, C | 1 |
| Kan, E | 1 |
| Coelho, MS | 1 |
| Reside, J | 1 |
| Card, SJ | 1 |
| Tawil, PZ | 1 |
| Mahler, P | 1 |
| Mahler, F | 1 |
| Duruz, H | 1 |
| Ramazzina, M | 1 |
| Liguori, V | 1 |
| Mautone, G | 1 |
| Rahusen, FT | 1 |
| Weinhold, PS | 1 |
| Almekinders, LC | 1 |
| Bagul, A | 1 |
| Taha, R | 1 |
| Metcalfe, MS | 1 |
| Brook, NR | 1 |
| Nicholson, ML | 1 |
| Dalton, JD | 1 |
| Schweinle, JE | 1 |
| Abbott, CJ | 1 |
| Bouchier-Hayes, TA | 1 |
| Hunt, HA | 1 |
| Aleixo, PL | 1 |
| Monteiro, PR | 1 |
| da Silva, AC | 1 |
| Wardle, EN | 1 |
Clinical Trials (6)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-Blind, 7-Day Study of the Efficacy and Safety of Rofecoxib Versus Placebo and Diclofenac in Patients With Acute Painful Rotator Cuff Syndrome[NCT00140933] | Phase 3 | 274 participants | Interventional | 2003-04-30 | Terminated | ||
| Efficacy and Security of Combined Analgesia (Opioid and Anti-inflammatory Agent) to Control Pain in Children Seen in the Emergency Department for a Trauma of a Limb[NCT01189773] | Phase 4 | 200 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| An Open Label Randomized Multicenter Comparative Study On Celecoxib Efficacy And Safety Versus Non-Selective NSAID In Acute Pain Due To Ankle Sprain[NCT00446797] | Phase 4 | 278 participants (Actual) | Interventional | 2007-05-31 | Completed | ||
| Ibuprofen Versus Acetaminophen vs Their Combination in the Relief of Musculoskeletal Pain in the Emergency Setting[NCT01827475] | Phase 2 | 90 participants (Actual) | Interventional | 2010-07-31 | Completed | ||
| The Efficacy and Safety of Administration of the COX-2 Selective NSAID, Etoricoxib (120mg od. for 7 Days) Compared to Diclofenac (50 mg Tds. for 7 Days) and Placebo as Adjunct Treatment in the First 7 Days of Treatment of Acute Grade II Lateral Ankle Liga[NCT00954785] | Phase 4 | 0 participants (Actual) | Interventional | 2009-11-30 | Withdrawn (stopped due to The study was terminated by Merck USA. The company did not supply drugs for the study.) | ||
| A Randomized, Double-Blind, Parallel-Group Study Comparing the Safety and Effectiveness of Acetaminophen Extended Release (3900 mg/Day) and Ibuprofen (1200 mg/Day) in the Treatment of Ankle Sprains.[NCT00261560] | Phase 4 | 260 participants (Actual) | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Trial Outcomes
Change From Baseline at Day 3 in Pain Visual Analog Scale (VAS) - Per Protocol Population
"Assessment of ankle pain by VAS: 100 mm horizontal line with left end being No Pain & right end being Worst Possible Pain. Participants drew vertical line on horizontal scale to best reflect current pain on full weight bearing of injured ankle. Distance from left end of line to mark. Change: mean score at day 3 minus mean score at baseline" (NCT00446797)
Timeframe: Baseline and day 3
| Intervention | scores on a scale (Mean) |
|---|---|
| Celecoxib | -44.88 |
| nsNSAIDs | -40.76 |
Change From Baseline in Pain Visual Analog Scale (VAS) - Modified Intent to Treat Population
"Assessment of ankle pain by VAS: 100 mm horizontal line, left end being No Pain & right end being Worst Possible Pain. Participants drew vertical line on horizontal scale to best reflect current pain on full weight bearing of injured ankle. Distance from left end of line to mark. Change: mean score at observation minus mean score at baseline" (NCT00446797)
Timeframe: Baseline and days 2, 3 and 7
| Intervention | scores on a scale (Mean) | ||
|---|---|---|---|
| Day 2 | Day 3 | Day 7 | |
| Celecoxib | -29.25 | -44.87 | -61.17 |
| nsNSAIDs | -25.98 | -40.75 | -57.89 |
Modified Brief Pain Inventory Short Form (m-BPI-sf) - Pain Interference Index
"m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period.~The pain interference index is the average of pain interference questions 5A to 5G. Scale: 0 = does not interfere to 10 = completely interferes" (NCT00446797)
Timeframe: Days 2, 3 and 7
| Intervention | scores on a scale (Mean) | ||
|---|---|---|---|
| Day 2 (N = 134, 133) | Day 3 (N = 135, 131) | Day 7 (N = 133, 125) | |
| Celecoxib | 4.07 | 2.79 | 1.28 |
| nsNSAIDs | 4.01 | 2.83 | 1.33 |
Modified Brief Pain Inventory Short Form (m-BPI-sf) - Pain Interference Question 5A
"m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period.~Q5A: Subject response to 'how, during the past 24 hours, pain has interfered with your general activity. Scale: 0 = does not interfere to 10 = completely interferes" (NCT00446797)
Timeframe: Days 2, 3 and 7
| Intervention | scores on a scale (Mean) | ||
|---|---|---|---|
| Day 2 (N = 134, 133) | Day 3 (N = 135, 131) | Day 7 (N = 133, 125) | |
| Celecoxib | 5.40 | 3.65 | 1.78 |
| nsNSAIDs | 5.37 | 4.07 | 1.90 |
Modified Brief Pain Inventory Short Form (m-BPI-sf) - Pain Interference Question 5B
"m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period.~Q5B: Subject response to 'how, during the past 24 hours, pain has interfered with your mood'. Scale: 0 = does not interfere to 10 = completely interferes" (NCT00446797)
Timeframe: Days 2, 3 and 7
| Intervention | scores on a scale (Mean) | ||
|---|---|---|---|
| Day 2 (N = 134, 133) | Day 3 (N = 135, 131) | Day 7 (N = 133, 125) | |
| Celecoxib | 3.72 | 2.43 | 1.17 |
| nsNSAIDs | 3.64 | 2.38 | 1.26 |
Modified Brief Pain Inventory Short Form (m-BPI-sf) - Pain Interference Question 5C
"m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period.~Q5C: Subject response to 'how, during the past 24 hours, pain has interfered with your walking ability'. Scale: 0 = does not interfere to 10 = completely interferes" (NCT00446797)
Timeframe: Days 2, 3 and 7
| Intervention | scores on a scale (Mean) | ||
|---|---|---|---|
| Day 2 (N = 134, 133) | Day 3 (N = 135, 131) | Day 7 (N = 133, 125) | |
| Celecoxib | 5.10 | 3.58 | 1.65 |
| nsNSAIDs | 5.11 | 3.69 | 1.62 |
Modified Brief Pain Inventory Short Form (m-BPI-sf) - Pain Interference Question 5D
"m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period.~Q5D: Subject response to 'how, during the past 24 hours, pain has interfered with your normal work (work outside the home and housework)'. Scale: 0 = does not interfere to 10 = completely interferes" (NCT00446797)
Timeframe: Days 2, 3 and 7
| Intervention | scores on a scale (Mean) | ||
|---|---|---|---|
| Day 2 (N = 134, 133) | Day 3 (N = 135, 131) | Day 7 (N = 133, 125) | |
| Celecoxib | 5.29 | 4.04 | 1.84 |
| nsNSAIDs | 5.39 | 4.04 | 1.87 |
Modified Brief Pain Inventory Short Form (m-BPI-sf) - Pain Interference Question 5E
"m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period.~Q5E: Subject response to 'how, during the past 24 hours, pain has interfered with your relations with other people'. Scale: 0 = does not interfere to 10 = completely interferes" (NCT00446797)
Timeframe: Days 2, 3 and 7
| Intervention | scores on a scale (Mean) | ||
|---|---|---|---|
| Day 2 (N = 134, 133) | Day 3 (N = 135, 131) | Day 7 (N = 133, 125) | |
| Celecoxib | 2.70 | 1.81 | 0.80 |
| nsNSAIDs | 2.67 | 1.69 | 0.78 |
Modified Brief Pain Inventory Short Form (m-BPI-sf) - Pain Interference Question 5F
"m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period.~Q5F: Subject response to 'how, during the past 24 hours, pain has interfered with your sleep'. Scale: 0 = does not interfere to 10 = completely interferes" (NCT00446797)
Timeframe: Days 2, 3 and 7
| Intervention | scores on a scale (Mean) | ||
|---|---|---|---|
| Day 2 (N = 134, 133) | Day 3 (N = 135, 131) | Day 7 (N = 133, 125) | |
| Celecoxib | 2.97 | 1.90 | 0.68 |
| nsNSAIDs | 2.87 | 1.86 | 0.82 |
Modified Brief Pain Inventory Short Form (m-BPI-sf) - Pain Interference Question 5G
"m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period.~Q5G: Subject response to 'how, during the past 24 hours, pain has interfered with your enjoyment of life'. Scale: 0 = does not interfere to 10 = completely interferes" (NCT00446797)
Timeframe: Days 2, 3 and 7
| Intervention | scores on a scale (Mean) | ||
|---|---|---|---|
| Day 2 (N = 134, 133) | Day 3 (N = 135, 131) | Day 7 (N = 133, 125) | |
| Celecoxib | 3.33 | 2.13 | 1.07 |
| nsNSAIDs | 2.99 | 2.06 | 1.10 |
Modified Brief Pain Inventory Short Form (m-BPI-sf) - Pain Severity Index
"m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period.~Pain severity index is the average of the pain severity questions 1 to 4. Scale: 0 = no pain to 10 = pain as bad as you can imagine" (NCT00446797)
Timeframe: Days 2, 3 and 7
| Intervention | scores on a scale (Mean) | ||
|---|---|---|---|
| Day 2 (N = 134, 133) | Day 3 (N = 135, 131) | Day 7 (N = 133, 125) | |
| Celecoxib | 4.24 | 2.84 | 1.37 |
| nsNSAIDs | 4.48 | 3.26 | 1.68 |
Modified Brief Pain Inventory Short Form (m-BPI-sf) - Pain Severity Question 1
"m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period.~Q1: Subject response to 'describe your pain at its worst in the last 24 hours'. Scale: 0 = no pain to 10 = pain as bad as you can imagine" (NCT00446797)
Timeframe: Days 1, 3 and 7
| Intervention | scores on a scale (Mean) | ||
|---|---|---|---|
| Day 2 (N = 134, 133) | Day 3 (N = 135, 131) | Day 7 (N = 133, 125) | |
| Celecoxib | 5.71 | 3.81 | 2.08 |
| nsNSAIDs | 5.90 | 4.44 | 2.38 |
Modified Brief Pain Inventory Short Form (m-BPI-sf) - Pain Severity Question 2
"m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period.~Q2: Subject response to 'describe your pain at its least in the last 24 hours'. Scale: 0 = no pain to 10 = pain as bad as you can imagine" (NCT00446797)
Timeframe: Days 2, 3 and 7
| Intervention | scores on a scale (Mean) | ||
|---|---|---|---|
| Day 2 (N = 133, 133) | Day 3 (N = 135, 131) | Day 7 (N = 133, 125) | |
| Celecoxib | 3.25 | 2.07 | 0.83 |
| nsNSAIDs | 3.36 | 2.40 | 1.16 |
Modified Brief Pain Inventory Short Form (m-BPI-sf) - Pain Severity Question 3
"m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period.~Q3: Subject response to 'describe your pain on the average'. Scale: 0 = no pain to 10 = pain as bad as you can imagine" (NCT00446797)
Timeframe: Days 2, 3 and 7
| Intervention | scores on a scale (Mean) | ||
|---|---|---|---|
| Day 2 (N = 134, 133) | Day 3 (N = 135, 131) | Day 7 (N = 133, 125) | |
| Celecoxib | 4.34 | 2.90 | 1.41 |
| nsNSAIDs | 4.41 | 3.26 | 1.74 |
Modified Brief Pain Inventory Short Form (m-BPI-sf) - Pain Severity Question 4
"m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period.~Q4: Subject response to 'how much pain you have right now'. Scale: 0 = no pain to 10 = pain as bad as you can imagine" (NCT00446797)
Timeframe: Days 2, 3 and 7
| Intervention | scores on a scale (Mean) | ||
|---|---|---|---|
| Day 2 (N = 134, 133) | Day 3 (N =135, 131) | Day 7 (N = 133, 125) | |
| Celecoxib | 3.64 | 2.58 | 1.14 |
| nsNSAIDs | 4.23 | 2.92 | 1.43 |
Number of Subjects Responding (Improving) - MITT Population
The number of subjects showing a response: a decrease of at least 20 mm (that is improvement) on the pain visual analog scale (VAS) scale (NCT00446797)
Timeframe: Days 2, 3 and 7
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| Day 2 - response (N=134, 133) | Day 2 - no response | Day 3 - response (N=135, 131) | Day 3 - no response | Day 7 - response (N=133, 125) | Day 7 - no response | |
| Celecoxib | 91 | 43 | 124 | 11 | 129 | 4 |
| nsNSAIDs | 79 | 54 | 116 | 15 | 120 | 5 |
Pain Relief - MITT Population
"Subject's response to the statement My relief from starting pain is. Scale from 0 = None to 4 = Complete." (NCT00446797)
Timeframe: Days 2, 3 and 7
| Intervention | participants (Number) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 2 - None (N=135, 132) | Day 2 - A little | Day 2 - Some | Day 2 - A lot | Day 2 -Complete | Day 3 - None (N=135, 131) | Day 3 - A little | Day 3 - Some | Day 3 - A lot | Day 3 -Complete | Day 7 - None (N=133, 125) | Day 7 - A little | Day 7 - Some | Day 7 - A lot | Day 7 -Complete | |
| Celecoxib | 8 | 25 | 49 | 52 | 1 | 0 | 15 | 33 | 84 | 3 | 1 | 6 | 7 | 77 | 42 |
| nsNSAIDs | 5 | 33 | 52 | 42 | 0 | 1 | 21 | 46 | 60 | 3 | 1 | 3 | 15 | 80 | 26 |
Physician Global Assessment of Ankle Injury
Investigator evaluation of overall severity of ankle injury. Scale: 5 point from 1 = Very mild (very mild signs and symptoms of ankle sprain) to 5 =Very severe (very severe signs and symptoms of ankle sprain) (NCT00446797)
Timeframe: Days 3 and 7
| Intervention | participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Day 3 - very mild (N=134, 131) | Day 3 - mild | Day 3 - moderate | Day 3 - severe | Day 3 - very severe | Day 7 - very mild (N=132, 125) | Day 7 - mild | Day 7 - moderate | Day 7 - severe | Day 7 - very severe | |
| Celecoxib | 20 | 71 | 40 | 2 | 1 | 87 | 38 | 7 | 0 | 0 |
| nsNSAIDs | 12 | 79 | 38 | 2 | 0 | 70 | 47 | 7 | 1 | 0 |
Subject Assessment of Normal Function / Activity
"Subject response to question: How does your ankle injury affect your walking and normal activity? Scale from 1 = Normal walking/activity and no pain to 5 = Severely restricted walking due to pain and can't resume normal activities (normal activities defined as all activity that a subject did on a routine basis, including work and recreation)" (NCT00446797)
Timeframe: Days 2, 3 and 7
| Intervention | participants (Number) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 2 - normal no pain (N =135, 133) | Day 2 - normal with pain | Day 2 - mildly restricted | Day 2 - moderately restricted | Day 2 - severely restricted | Day 3 - normal no pain (N = 135, 131) | Day 3 - normal with pain | Day 3 - mildly restricted | Day 3 - moderately restricted | Day 3 - severely restricted | Day 7 - normal no pain (N = 133, 125) | Day 7 - normal with pain | Day 7 - mildly restricted | Day 7 - moderately restricted | Day 7 - severely restricted | |
| Celecoxib | 5 | 40 | 59 | 19 | 12 | 18 | 52 | 49 | 14 | 2 | 62 | 55 | 11 | 4 | 1 |
| nsNSAIDs | 2 | 30 | 55 | 39 | 7 | 13 | 46 | 57 | 11 | 4 | 43 | 68 | 8 | 3 | 3 |
Subject's Global Assessment of Ankle Injury
"Subject response to question: Considering all the ways your ankle injury affects you, how are you doing today? Scale: 5 point from 1 = very good (no symptoms and no limitation of normal activities) to 5 = very poor (very severe symptoms which are intolerable and inability to carry out all normal activities)." (NCT00446797)
Timeframe: Days 2, 3 and 7
| Intervention | participants (Number) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 2 - Very good (no symptoms) (N=135, 133) | Day 2 - Good (mild symptoms) | Day 2 - Fair (moderate symptoms) | Day 2 - Poor (severe symptoms) | Day 2- Very poor (very severe symptoms) | Day 3 - Very good (no symptoms) (N=135, 131) | Day 3 - Good (mild symptoms) | Day 3 - Fair (moderate symptoms) | Day 3 - Poor (severe symptoms) | Day 3 - Very poor (very severe symptoms) | Day 7 - Very good (no symptoms) (N=133, 125) | Day 7 - Good (mild symptoms) | Day 7 - Fair (moderate symptoms) | Day 7 - Poor (severe symptoms) | Day 7 - Very poor (very severe symptoms) | |
| Celecoxib | 1 | 40 | 76 | 17 | 1 | 8 | 68 | 54 | 5 | 0 | 53 | 61 | 17 | 2 | 0 |
| nsNSAIDs | 1 | 31 | 80 | 19 | 2 | 6 | 55 | 63 | 7 | 0 | 37 | 63 | 21 | 4 | 0 |
Need for Rescue Pain Relief
The need for additional analgesics (NCT01827475)
Timeframe: 1 hour
| Intervention | participants (Number) |
|---|---|
| Ibuprofen | 11 |
| Acetaminophen | 10 |
| Ibuprofen-acetaminophen Combination | 5 |
Pain Severity
Pain score on 100 mm VAS from 0 (no pain) to 100 (worst pain) (NCT01827475)
Timeframe: 1 hour
| Intervention | mm (Mean) |
|---|---|
| Ibuprofen | 39 |
| Acetaminophen | 43 |
| Ibuprofen-acetaminophen Combination | 42 |
Reviews
2 reviews available for acetaminophen and Bruise
| Article | Year |
|---|---|
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury.
Topics: Acetaminophen; Acute Disease; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Anti-Infl | 2020 |
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury.
Topics: Acetaminophen; Acute Disease; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Anti-Infl | 2020 |
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury.
Topics: Acetaminophen; Acute Disease; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Anti-Infl | 2020 |
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury.
Topics: Acetaminophen; Acute Disease; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Anti-Infl | 2020 |
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury.
Topics: Acetaminophen; Acute Disease; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Anti-Infl | 2020 |
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury.
Topics: Acetaminophen; Acute Disease; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Anti-Infl | 2020 |
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury.
Topics: Acetaminophen; Acute Disease; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Anti-Infl | 2020 |
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury.
Topics: Acetaminophen; Acute Disease; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Anti-Infl | 2020 |
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury.
Topics: Acetaminophen; Acute Disease; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Anti-Infl | 2020 |
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury.
Topics: Acetaminophen; Acute Disease; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Anti-Infl | 2020 |
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury.
Topics: Acetaminophen; Acute Disease; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Anti-Infl | 2020 |
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury.
Topics: Acetaminophen; Acute Disease; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Anti-Infl | 2020 |
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury.
Topics: Acetaminophen; Acute Disease; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Anti-Infl | 2020 |
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury.
Topics: Acetaminophen; Acute Disease; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Anti-Infl | 2020 |
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury.
Topics: Acetaminophen; Acute Disease; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Anti-Infl | 2020 |
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury.
Topics: Acetaminophen; Acute Disease; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Anti-Infl | 2020 |
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury.
Topics: Acetaminophen; Acute Disease; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Anti-Infl | 2020 |
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury.
Topics: Acetaminophen; Acute Disease; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Anti-Infl | 2020 |
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury.
Topics: Acetaminophen; Acute Disease; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Anti-Infl | 2020 |
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury.
Topics: Acetaminophen; Acute Disease; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Anti-Infl | 2020 |
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury.
Topics: Acetaminophen; Acute Disease; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Anti-Infl | 2020 |
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury.
Topics: Acetaminophen; Acute Disease; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Anti-Infl | 2020 |
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury.
Topics: Acetaminophen; Acute Disease; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Anti-Infl | 2020 |
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury.
Topics: Acetaminophen; Acute Disease; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Anti-Infl | 2020 |
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury.
Topics: Acetaminophen; Acute Disease; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Anti-Infl | 2020 |
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury.
Topics: Acetaminophen; Acute Disease; Administration, Oral; Analgesics; Analgesics, Opioid; Anti-Inflammator | 2015 |
Trials
5 trials available for acetaminophen and Bruise
| Article | Year |
|---|---|
Periapical Microsurgery: The Effects of Locally Injected Dexamethasone on Pain, Swelling, Bruising, and Wound Healing.
Topics: Acetaminophen; Adrenal Cortex Hormones; Adult; Analgesics, Non-Narcotic; Analgesics, Opioid; Anesthe | 2016 |
Double-blind, randomized, controlled study on the efficacy and safety of a novel diclofenac epolamine gel formulated with lecithin for the treatment of sprains, strains and contusions.
Topics: Acetaminophen; Administration, Topical; Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Ankle Inj | 2003 |
Pre-incision infiltration of local anesthetic reduces postoperative pain with no effects on bruising and wound cosmesis after thyroid surgery.
Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Analgesics, Opioid; Anesthesia, Local; Anesthetics, | 2005 |
Randomized controlled noninferiority trial to compare extended release acetaminophen and ibuprofen for the treatment of ankle sprains.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Ankle Injuries; Arthralgia; Contusions; Double-Blind Method | 2006 |
A comparison of the efficacy of naproxen sodium and a paracetamol/dextropropoxyphene combination in the treatment of soft-tissue disorders.
Topics: Acetaminophen; Adult; Athletic Injuries; Clinical Trials as Topic; Contusions; Dextropropoxyphene; D | 1980 |
Other Studies
3 other studies available for acetaminophen and Bruise
| Article | Year |
|---|---|
Nonsteroidal anti-inflammatory drugs and acetaminophen in the treatment of an acute muscle injury.
Topics: Acetaminophen; Acute Disease; Analgesics, Non-Narcotic; Animals; Anti-Inflammatory Agents, Non-Stero | 2004 |
[Clinical observations and analgesic properties of the association of paracetamol and phenylbutazone].
Topics: Acetaminophen; Back Pain; Contusions; Ear Diseases; Headache; Humans; Joint Diseases; Muscular Disea | 1966 |
Fibrinogen in liver disease.
Topics: Acetaminophen; Chemical and Drug Induced Liver Injury; Cholangitis; Cholestasis; Contusions; Endotox | 1974 |